Dyne Therapeutics, Inc.
DYN
$14.51
$0.523.72%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -28.83% | 7.81% | -49.19% | 0.83% | 1.48% |
Total Depreciation and Amortization | 11.56% | 2.74% | 9.77% | 3.37% | -3.26% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 27.70% | 24.91% | 40.90% | -71.40% | 242.81% |
Change in Net Operating Assets | 29.16% | -135.86% | 234.17% | 112.92% | -228.59% |
Cash from Operations | -25.56% | -13.01% | -36.02% | 30.14% | -124.35% |
Capital Expenditure | 8.74% | -324.90% | 70.48% | -348.69% | -132.93% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 116.33% | 22.01% | -259.17% | 106.70% | -783.64% |
Cash from Investing | 109.11% | 17.49% | -273.64% | 106.21% | -786.51% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 3,784.52% | -79.81% | -95.26% | -6.99% | 277,714.97% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 3,784.52% | -79.81% | -95.26% | -6.99% | 277,714.97% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 138.06% | -27.21% | -122.61% | 124.09% | 1,831.66% |